Cargando…
Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review
Hereditary spastic paraplegia (HSP) is characterized by progressive lower limb spasticity. There is no disease-modifying treatment currently available. Therefore, standardized, validated outcome measures to facilitate clinical trials are urgently needed. We performed a scoping review of outcome meas...
Autores principales: | Siow, Sue-Faye, Yeow, Dennis, Rudaks, Laura I., Jia, Fangzhi, Wali, Gautam, Sue, Carolyn M., Kumar, Kishore R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10530989/ https://www.ncbi.nlm.nih.gov/pubmed/37761896 http://dx.doi.org/10.3390/genes14091756 |
Ejemplares similares
-
Reduced acetylated α-tubulin in SPAST hereditary spastic paraplegia patient PBMCs
por: Wali, Gautam, et al.
Publicado: (2023) -
Motor Evoked Potentials in Hereditary Spastic Paraplegia—A Systematic Review
por: Siow, Sue-Faye, et al.
Publicado: (2019) -
Mitochondrial Function in Hereditary Spastic Paraplegia: Deficits in SPG7 but Not SPAST Patient-Derived Stem Cells
por: Wali, Gautam, et al.
Publicado: (2020) -
Single cell morphology distinguishes genotype and drug effect in Hereditary Spastic Paraplegia
por: Wali, Gautam, et al.
Publicado: (2021) -
Pharmacological rescue of mitochondrial and neuronal defects in SPG7 hereditary spastic paraplegia patient neurons using high throughput assays
por: Wali, Gautam, et al.
Publicado: (2023)